Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan PLC

www.allergan.com

Latest From Allergan PLC

Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun

With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.

Deals Asia Pacific

FTC 'Ready' To Go After Abusive Citizen Petitions; Allergan Wants 'Substantive' FDA Responses

US FDA draft guidance on citizen petitions elicits comments of support, including call to exclude brand manufacturer petitions except in urgent situations.
Generic Drugs Biosimilars

FTC 'Ready' To Go After Abusive Citizen Petitions; Allergan Wants 'Substantive' FDA Responses

US FDA draft guidance on citizen petitions elicits comments of support, including call to exclude brand manufacturer petitions except in urgent situations.
Generic Drugs Biosimilars

NASH Drug Development Guidance Encourages Sponsors To Adopt Innovative Trial Designs

Although guidance appears to be free of surprises, US FDA once again made a push for sponsors to adopt seamless trial designs.
Clinical Trials Liver & Hepatic
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register